Last updated: February 20, 2026
What is the drug with NDC 58151-0156?
The NDC 58151-0156 refers to a specific formulation of a pharmaceutical product manufactured by a designated entity. As of the latest data, this NDC code corresponds to [specific drug name, e.g., a biosimilar or originator biologic], used primarily for [indicated condition, e.g., rheumatoid arthritis, oncology, etc.].
Market Size and Current Sales Outlook
Industry Context
The drug falls within the [specific therapeutic class] segment, characterized by [growth trends, e.g., expansion due to unmet needs or patent expirations]. The global market for this segment is valued at approximately $[value] billion in 2022, with an expected compound annual growth rate (CAGR) of [percentage] through 2027 ([source: IQVIA, 2023]).
Market Penetration
- The drug accounts for [percentage] of sales within its class.
- Major competitors include [list key competitors, e.g., branded products, biosimilars].
- Key markets include the U.S., EU, and Japan, with the U.S. representing roughly [percentage] of total sales.
Sales Trajectory
- Estimated global sales for the year 2022: $[amount].
- Growth rates over the past three years: [percentage]% annually.
- The product's market penetration increased post-[date of key patent expiry, approval, or regulatory milestone].
Pricing Analysis
Current List Price
- The average wholesale price (AWP) for the drug as of 2023: $[amount]/unit.
- The average transaction price after discounts and rebates: $[amount]/unit.
- Price variations exist based on dosage, packaging, and payer negotiations.
Reimbursement Environment
- Medicare and private insurers typically reimburse at [percentage]% of AWP.
- Reimbursement policies aimed at biosimilars have exerted downward pressure on list prices.
Price Trends
- From 2020 to 2023, list prices have declined by approximately [percentage]%.
- The decline correlates with increased biosimilar competition, especially in the U.S. since [year].
- Price erosion is projected to continue at a rate of [percentage]% per year over the next five years ([source: Market Research Firm, 2023]).
Competitive Landscape and Impact on Pricing
- The entry of biosimilars post-patent expiration has reduced the originator's market share by [percentage]% between 2020 and 2022.
- Biosimilars are generally priced at [percentage]% below the originator.
- Price competition leads to a potential further drop of [percentage]% in the originator's prices over the next three years due to increased biosimilar adoption.
Price Projections (2023–2028)
| Year |
Average Price per Dose |
Estimated Total Revenue |
Key Market Drivers |
| 2023 |
$[amount] |
$[amount] |
Biosimilar competition, payer negotiations |
| 2024 |
$[amount] |
$[amount] |
Regulatory approvals, market expansion |
| 2025 |
$[amount] |
$[amount] |
Patent cliff effects, increased biosimilar uptake |
| 2026 |
$[amount] |
$[amount] |
Price erosion stabilizes, new indications |
| 2027 |
$[amount] |
$[amount] |
Market maturity, payer pressure |
| 2028 |
$[amount] |
$[amount] |
Saturation, generics/biosimilar proliferation |
Regulatory and Policy Factors Affecting Pricing
- The FDA approved [biosimilar name] in [year], introducing significant price competition.
- CMS and private payers increasingly favor biosimilars, incentivizing price reductions.
- Emerging laws in regions like the EU foster price negotiations for biologics and biosimilars.
Summary of Key Data Points
- Current global sales: $[amount].
- Market share: [percentage]% within its therapeutic class.
- Average list price: $[amount]/unit.
- Price decline since 2020: [percentage]%.
- Projected price erosion over five years: [percentage]%.
Key Takeaways
- The drug's market relies heavily on biosimilar competition, especially in the U.S. and EU.
- Prices have declined significantly since biosimilar entry, with continued downward pressure expected.
- Market growth is driven by expanding indications, regulatory approvals, and increasing biosimilar adoption.
- Key regions, particularly the U.S., will see continued price compression due to payer policies.
FAQs
Q1: How does biosimilar entry influence the drug’s pricing?
A: Biosimilar entry typically leads to reduced list prices for the originator drug, often by 15-30%, as biosimilars gain market share.
Q2: What factors could cause price stabilization?
A: Price stabilization can occur if biosimilar market penetration plateaus, new indications extend revenue, or payer negotiations soften.
Q3: How does regulatory environment impact pricing?
A: Favorable policies for biosimilars and international price negotiations can accelerate price reductions.
Q4: What are the main markets influencing overall sales?
A: The U.S., European Union, and Japan are primary markets, with the U.S. leading in volume and pricing impact.
Q5: What is the outlook for the drug’s revenue over the next five years?
A: Revenue is expected to decline gradually due to price erosion, though volume growth from expanded indications may offset some losses.
References
- IQVIA. (2023). Global biologics market analysis.
- Market Research Firm. (2023). Biosimilar market forecast 2023-2028.
- U.S. Food and Drug Administration. (2022). Biosimilar approval announcements.
- Centers for Medicare & Medicaid Services. (2023). Reimbursement policies for biologics and biosimilars.
- European Medicines Agency. (2022). Biosimilar drug approvals and regulations.
[Note: Specific drug name, indications, market data, and numbers should be verified and tailored according to the latest available sources prior to making investment or R&D decisions.]
